Gilbert & Cook Inc. Acquires 341 Shares of Johnson & Johnson $JNJ

Gilbert & Cook Inc. lifted its holdings in Johnson & Johnson (NYSE:JNJ) by 4.2% in the second quarter, Holdings Channel reports. The fund owned 8,508 shares of the company’s stock after purchasing an additional 341 shares during the quarter. Gilbert & Cook Inc.’s holdings in Johnson & Johnson were worth $1,300,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. Clark Asset Management LLC boosted its position in shares of Johnson & Johnson by 51.6% during the second quarter. Clark Asset Management LLC now owns 8,884 shares of the company’s stock valued at $1,357,000 after buying an additional 3,025 shares during the period. Apexium Financial LP lifted its stake in shares of Johnson & Johnson by 10.7% during the 1st quarter. Apexium Financial LP now owns 23,989 shares of the company’s stock worth $3,978,000 after acquiring an additional 2,310 shares during the last quarter. Avanza Fonder AB boosted its holdings in Johnson & Johnson by 2.9% during the 2nd quarter. Avanza Fonder AB now owns 234,647 shares of the company’s stock valued at $35,842,000 after acquiring an additional 6,566 shares during the period. Tokio Marine Asset Management Co. Ltd. grew its position in Johnson & Johnson by 7.0% in the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 73,350 shares of the company’s stock valued at $12,164,000 after acquiring an additional 4,816 shares during the last quarter. Finally, Klingman & Associates LLC increased its stake in Johnson & Johnson by 13.4% in the first quarter. Klingman & Associates LLC now owns 16,984 shares of the company’s stock worth $2,817,000 after purchasing an additional 2,005 shares during the period. 69.55% of the stock is owned by institutional investors.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on JNJ shares. JPMorgan Chase & Co. upped their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a report on Tuesday, September 16th. Raymond James Financial boosted their price objective on shares of Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a research report on Wednesday, October 15th. The Goldman Sachs Group raised their target price on shares of Johnson & Johnson from $186.00 to $212.00 and gave the stock a “buy” rating in a research report on Thursday, October 9th. Wall Street Zen upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Saturday, September 13th. Finally, Bank of America raised their price objective on Johnson & Johnson from $198.00 to $204.00 and gave the stock a “neutral” rating in a report on Wednesday, October 15th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average target price of $199.05.

Johnson & Johnson Price Performance

JNJ opened at $189.02 on Friday. The firm has a market capitalization of $455.40 billion, a PE ratio of 18.25, a price-to-earnings-growth ratio of 2.19 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The business’s 50-day moving average is $183.28 and its two-hundred day moving average is $167.66. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $194.48.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The business had revenue of $24.02 billion during the quarter. Research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s payout ratio is currently 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.